Resolution Biology of Fever-Related Inflammation: Mechanisms, Clinical Insights, and Emerging Therapeutics

Abstract

Fever remains a cardinal clinical sign of infection and inflammation, characterized by a regulated elevation of core body temperature. Recent advances in resolution biology have elucidated the molecular and cellular pathways underpinning the cessation of fever-related inflammation, offering novel therapeutic implications. This review synthesizes current evidence on the epidemiology, pathophysiology, clinical features, diagnostic criteria, and management of fever-associated inflammation, integrating emerging resolution-focused strategies and guideline-based recommendations for clinicians.

Introduction

Fever, or pyrexia, is a physiologically orchestrated response to infection or tissue injury. Traditionally considered a hallmark of inflammation, fever is mediated by endogenous pyrogens that reset the hypothalamic thermoregulatory set point. While the mechanisms initiating fever are well described, the processes governing the resolution of fever-associated inflammation have only recently been brought to light. Understanding resolution biology is pivotal for developing interventions that not only suppress excessive inflammation but also actively promote tissue homeostasis and recovery.

Epidemiology / Disease Burden

Fever is among the most frequent presenting symptoms in both outpatient and inpatient clinical settings worldwide. Epidemiological studies estimate that up to 75% of acute care visits in pediatric populations and 30–40% in adults involve a complaint of fever. Infectious etiologies predominate, but a significant proportion of fevers are attributable to non-infectious inflammatory, autoimmune, and neoplastic conditions. The global disease burden of fever-related illnesses, particularly in low- and middle-income countries, contributes substantially to healthcare utilization, morbidity, and mortality, underscoring the necessity for optimized diagnostic and management approaches.

Pathophysiology

The febrile response originates from the recognition of pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) by innate immune cells, leading to the production of pro-inflammatory cytokines such as interleukin-1β (IL-1β), interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α). These cytokines act on the hypothalamus to induce prostaglandin E2 (PGE2) synthesis, thereby elevating the thermoregulatory set point. Resolution biology focuses on the active biochemical processes that terminate inflammation, including the generation of specialized pro-resolving mediators (SPMs) such as lipoxins, resolvins, protectins, and maresins. These mediators promote efferocytosis, dampen neutrophil recruitment, and restore tissue integrity without inducing immunosuppression.

Risk Factors

Risk factors for dysregulated or persistent fever include extremes of age, immunocompromised states (e.g., HIV/AIDS, chemotherapy, organ transplantation), chronic diseases (e.g., diabetes, chronic kidney disease), and genetic predispositions affecting cytokine signaling or resolution pathways. Nosocomial infections and invasive procedures further increase susceptibility to complicated fever profiles and protracted inflammatory responses.

Clinical Features

Fever typically presents with an elevated body temperature above 38°C, accompanied by chills, rigors, malaise, myalgia, and headache. Clinical features may vary according to the underlying etiology and the host's immune status. Inflammatory fevers may be associated with organ-specific symptoms (e.g., cough in pneumonia, dysuria in urinary tract infections) or systemic findings such as tachycardia and hypotension in severe cases. Recognition of fever patterns and associated features is critical for differential diagnosis and risk stratification.

Diagnosis

Diagnosis of fever-related inflammation involves a structured approach, beginning with detailed history taking and physical examination. Laboratory investigations commonly include complete blood count, inflammatory markers (C-reactive protein, erythrocyte sedimentation rate, procalcitonin), blood cultures, and site-specific microbiological or imaging studies. Recent advances have incorporated biomarker panels and molecular diagnostics to differentiate infectious from non-infectious causes and to identify resolution-phase mediators. Identification of persistent or relapsing fever necessitates evaluation for immune dysregulation and autoinflammatory syndromes.

Treatment & Management

Management of fever-related inflammation is twofold: addressing the underlying etiology (antimicrobial, anti-inflammatory, or immunosuppressive therapy as appropriate) and symptomatic control with antipyretics (acetaminophen, NSAIDs) where clinically indicated. Emerging evidence supports a nuanced approach to antipyresis, as indiscriminate suppression of fever may impede host defense and resolution processes. Supportive care, including fluid management, oxygenation, and monitoring for complications such as sepsis or organ dysfunction, remains integral, particularly in vulnerable populations.

Recent Advances / Emerging Therapies

Resolution biology has catalyzed the development of novel therapeutics that harness endogenous pro-resolving pathways. Synthetic analogs of SPMs, modulators of lipid mediator biosynthesis, and agents targeting efferocytosis pathways are under investigation for their ability to accelerate resolution, limit tissue damage, and reduce the risk of chronic inflammation or post-infectious sequelae. Clinical trials assessing the efficacy and safety of these agents in diverse patient populations are ongoing. Additionally, omics-based approaches are refining personalized fever management and prognosis prediction.

Guideline Recommendations

Current clinical guidelines emphasize the importance of identifying the underlying cause of fever, judicious use of diagnostic resources, and evidence-based antimicrobial stewardship. Recent international consensus statements highlight the role of resolution biology in modulating inflammation and recommend restraint in the routine use of antipyretics, particularly in uncomplicated viral infections. Guidelines advocate for individualized care in immunocompromised and critically ill patients, incorporating emerging biomarkers and pro-resolving interventions where available.

Conclusion

Resolution biology has transformed our understanding of fever-related inflammation, revealing active molecular programs that restore homeostasis and prevent collateral tissue injury. Integrating mechanisms of resolution into clinical practice offers promising avenues for targeted therapy, improved patient outcomes, and reduced healthcare burden. Continued research and translation of resolution-based strategies are essential for optimizing the management of fever across diverse clinical contexts.